Abstract
AEOL-10150, a small-molecule antioxidant analogous to the catalytic site of superoxide dismutase, is under development by Aeolus (formerly Incara) as a potential subcutaneous treatment for amyotrophic lateral sclerosis (ALS), stroke, spinal cord injury, lung inflammation and mucositis. The compound is currently undergoing a phase I clinical trial for ALS. In October 2005, the company had applied for Fast Track status, and planned to submit a special protocol assessment for a pivotal phase II/III trial.
MeSH terms
-
Animals
-
Antioxidants / adverse effects
-
Antioxidants / chemistry
-
Antioxidants / pharmacokinetics
-
Antioxidants / therapeutic use*
-
Clinical Trials as Topic
-
Humans
-
Lung Diseases / drug therapy
-
Metalloporphyrins / adverse effects
-
Metalloporphyrins / chemistry
-
Metalloporphyrins / pharmacology
-
Metalloporphyrins / therapeutic use*
-
Molecular Structure
-
Neoplasms / drug therapy
-
Nervous System Diseases / drug therapy
-
Neuroprotective Agents / adverse effects
-
Neuroprotective Agents / chemistry
-
Neuroprotective Agents / pharmacology
-
Neuroprotective Agents / therapeutic use*
-
Structure-Activity Relationship
-
Treatment Outcome
Substances
-
AEOL 10150
-
Antioxidants
-
Metalloporphyrins
-
Neuroprotective Agents